Correction — BridGene Biosciences
Summary
BridGene Biosciences completed a $28 million Series B+ financing round led by Bayland Capital with participation from several investors. The company will use the proceeds to advance BGC-515 through clinical development toward Phase 2. It will also fund a second program expected to enter the clinic in 2027 and support additional oncology and autoimmune disease programs. The round also strengthens BridGene’s ability to expand strategic collaborations around its IMTAC chemoproteomic platform.
Funding
Amount
$28.0M
Total raised
Date
January 27, 2026
Announcement date
Investors
Proxima Ventures
Lead investors
Company
bridgenebio.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected